Kairos PharmaKAPA
13F holders, Q1 2026 (March 31)11holders −3
2new positions
5sold out
$0.57avg. 13F price*
At the end of Q1 2026, 11 institutions reported holding Kairos Pharma Ltd. (KAPA) in their 13F filings, down 3 from Q4 2025. 2 opened new positions and 5 sold out. The largest holders were Vanguard Capital Management LLC ($130K), Geode Capital Management, LLC ($62K) and Vanguard Fiduciary Trust Co. ($36K).
- Company
- Kairos Pharma Ltd.
- CUSIP
- 48301N104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $9K |
| Exits | 5 | $286K |
All 13F filers, Q4 2025 → Q1 2026: 54,970 shares bought and 458,419 shares sold, net −403,449 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Vanguard Capital Management LLC | 0.00% | — | 231,878 | $130K |
| Geode Capital Management, LLC | 0.00% | Add +52.8% | 111,290 | $62K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 63,884 | $36K |
| SevenBridge Financial Group, LLC | 0.00% | No change | 44,286 | $30K |
| Aptus Capital Advisors, LLC | 0.00% | No change | 44,286 | $25K |
| Two Sigma Investments, LP | 0.00% | Reduce -57.9% | 39,543 | $22K |
| State Street Corp. | 0.00% | No change | 24,100 | $13K |
| HRT Financial LP | 0.00% | Add +1.2% | 21,575 | $12K |
| Two Sigma Securities, LLC | 0.00% | New | 16,247 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -6.3% | 3,962 | $2K |
| Citigroup Inc. | 0.00% | New | 10 | $6 |
"% of holder's portfolio" is KAPA's weight in each manager's 13F, not the share of Kairos Pharma Ltd. the manager owns.